Duchenne Muscular Dystrophy (DMD) is a serious disease that affects muscles, causing boys to lose the ability to walk between ages 7 and 13. It can lead to breathing problems and heart disease, often causing early death. This study tests a new medicine called ifetroban to help DMD patients, especially with heart issues. The study is a randomized, double-blind, placebo-controlled trial, meaning some people get the real medicine, while others get a placebo (a fake treatment), and neither the doctors nor patients know who gets which. The study lasts 12 months, and participants are divided into groups to receive different doses of ifetroban or a placebo. They will have regular check-ups, blood tests, and urine tests to see how the medicine affects them. Only boys aged 7 and older with DMD can join, and they must meet certain health criteria. They need to be stable on heart medicine and not have any other major illnesses. The study is still open for those with more serious heart problems.
- Study lasts for 12 months
- Participants will receive either ifetroban or a placebo
- Regular medical check-ups and tests are required